| Name | Title | Contact Details |
|---|
Patient Interaction is a Bronx, NY-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
United BioSource Corporation is one of the leading companies in the Healthcare, Pharmaceuticals, and Biotech sector.
United Claim Solutions was started by Joshua Carder in 2004. Joshua had been in the cost containment industry for a number of years, and through that experience realized there were efficiencies and solutions that could be introduced to lower medical and administrative costs for self-insured employers, labor organizations, payers and insurers. The mission of United Claim Solutions is to be a leader and innovator of products and services for healthcare payers. We will provide superior Service, Savings and Solutions to our customers while never compromising the quality of care delivered to covered individuals.
Neurotrope was formed in October 2012 to develop and market two product platforms, including a non-invasive diagnostic test for Alzheimer's Disease and a drug candidate called bryostatin for the treatment of Alzheimer's Disease, both of which are in the clinical testing stage. Neurotrope was formed for the primary purpose of commercializing certain technologies that were initially developed by Blanchette Rockefeller Neurosciences Institute ("BRNI") and its affiliates, for therapeutic or diagnostic applications for Alzheimer's Disease or other cognitive dysfunctions. These technologies have been under development since 1999 and have been financed through significant funding from a variety of non-investor sources. The Company expects that its first product, the diagnostic test for Alzheimer's Disease, will finish the testing phase of its development in 2015, whereupon the Company will evaluate the feasibility of its commercialization. In addition to bryostatin and the diagnostic test for Alzheimer's Disease, the Company intends to pursue development of two other technology platforms developed by and licensed from BRNI: the first, a platform for transporting drugs into the brain through the "blood-brain-barrier," and the second, a group of drugs for enhancing cognition, mood and alertness for neuropsychiatric conditions.
The Indiana Hemophilia & Thrombosis Center (IHTC) is the only federally recognized comprehensive hemophilia treatment center in Indiana and one of the largest centers in the nation. The IHTC is a 501(c)3 nonprofit entity that is dedicated to providing the best, most comprehensive care to people in Indiana with bleeding or clotting disorders and to their families. The IHTC is both nationally and internationally distinguished as a Center of Excellence for its leadership in bleeding disorder patient care, education and research.